Table 2.
Characteristics of the participants with complete immunization—corresponds to the heatmaps in Figs. 3, 4 and 5
| Vaccine | AstraZeneca | Janssen | Moderna | Pfizer |
|---|---|---|---|---|
| N. participants with complete immunization* | 5556 | 2458 | 2441 | 10227 |
| Age distribution | ||||
| 0–29 years | 570 (10.26) | 390 (15.87) | 197 (8.07) | 176 (1.72) |
| 30–39 years | 773 (13.91) | 383 (15.58) | 413 (16.92) | 404 (3.95) |
| 40–49 years | 1054 (18.97) | 581 (23.64) | 759 (31.09) | 418 (4.09) |
| 50–59 years | 1553 (27.95) | 1059 (43.08) | 967 (39.61) | 452 (4.42) |
| 60–69 years | 1575 (28.35) | 41 (1.67) | 82 (3.36) | 586 (5.73) |
| 70+ years | 31 (0.56) | 4 (0.16) | 23 (0.94) | 8191 (80.09) |
| Men | ||||
| Women | 4708 (84.74) | 1759 (71.56) | 1611 (66) | 3874 (37.88) |
| History of COVID-19 infection confirmed by testing | 374 (6.73) | 270 (10.98) | 154 (6.31) | 273 (2.67) |
| Reported any AEFI | 5143 (92.57) | 2015 (81.98 | 2286 (93.65) | 5394 (52.74) |
| Reported any AEFI after dose 1 | 5044 (90.78) | 2015 (81.98) | 1953 (80.01) | 4094 (40.03) |
| Reported any AEFI after dose 2 | 5044 (48.43) | 2015 (0) | 1953 (85.17) | 4094 (35.71) |
| Reported at least 1 well-known systemic AEFI* | 5044 (88.32) | 2015 (77.14) | 1953 (87.1) | 4094 (39.31) |
| Reported at least 1 well-known systemic AEFI* after dose 1 | 4772 (85.89) | 1896 (77.14) | 1363 (55.84) | 2617 (25.59) |
| Reported at least 1 well-known systemic AEFI*after dose 2 | 2173 (39.11) | NA | 1920 (78.66) | 2696 (26.36) |
| Reported fever after dose 1 | 1746 (31.43) | 544 (22.13) | 105 (4.3) | 89 (0.87) |
| Reported fever after dose 2 | 192 (3.46) | NA | 546 (22.37) | 203 (1.98) |
| Comorbidities (MedDRA System Organ Class) | ||||
| Immune system disorders | 95 (1.71) | 23 (0.94) | 79 (3.24) | 208 (2.03) |
| Respiratory, thoracic and mediastinal disorders | 480 (8.64) | 109 (4.43) | 266 (10.9) | 938 (9.17) |
| Hepatobiliary disorders | 12 (0.22) | 4 (0.16) | 8 (0.33) | 29 (0.28) |
| Nervous system disorders | 66 (1.19) | 21 (0.85) | 32 (1.31) | 193 (1.89) |
| Psychiatric disorders | 222 (4) | 117 (4.76) | 111 (4.55) | 186 (1.82) |
| Cardiac disorders | 221 (3.98) | 33 (1.34) | 81 (3.32) | 1959 (19.16) |
| Vascular disorders | 590 (10.62) | 139 (5.66) | 166 (6.8) | 2942 (28.77) |
| Renal and urinary disorders | 27 (0.49) | 2 (0.08) | 23 (0.94) | 236 (2.31) |
| Metabolism and nutrition disorders | 168 (3.02) | 10 (0.41) | 63 (2.58) | 835 (8.16) |
| Neoplasms benign, malignant and unspecified (incl. cysts and polyps) | 43 (0.77) | 20 (0.81) | 27 (1.11) | 239 (2.34) |
| Pregnancy, puerperium and perinatal conditions | 1 (0.02) | 3 (0.12) | 33 (1.35) | 12 (0.12) |
| Other | 627 (11.29) | 199 (8.1) | 315 (12.9) | 1305 (12.76) |
Data reported as n (%)
AEFI adverse events following immunization, NA not applicable
*Fever (body temperature 38 °C or higher), arthralgia, myalgia, nausea, pyrexia, headache, malaise, chills, fatigue